Efficacy and Safety of Chidamide in Combination with PD-1 Inhibitor and Radiotherapy for HER2-Negative Advanced Breast Cancer: Study Protocol of a Single Arm Prospective Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Blancas I, Aguirre E, Morales S, et al. Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens. Clin Transl Oncol. 2019;21(4):459–466. doi:10.1007/s12094-018-1946-9
   PubMed Web of Science ®Google Scholar
• Rha SU, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Tr. 2005;90(3):215–221. doi:10.1007/s10549-004-2468-4
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, Phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828. doi:10.1016/S0140-6736(20)32531-9
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here. Cancer. 2018;124(10):2086–2103. doi:10.1002/cncr.31272
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–867. doi:10.1200/JCO.2011.41.0902
   PubMed Web of Science ®Google Scholar
• Gao Y, Nihira NT, Bu X, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22(9):1064–1075. doi:10.1038/s41556-020-0562-4
   PubMed Web of Science ®Google Scholar
• Bissonnette RP, Cesario RM, Goodenow B, Shojaei F, Gillings M. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors. BMC Cancer. 2021;21(1):969. doi:10.1186/s12885-021-08702-x
   PubMed Web of Science ®Google Scholar
• Zhang W, Shen H, Zhang Y, et al. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells. Cancer Med. 2019;8(5):2104–2113. doi:10.1002/cam4.2097
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang W, Zhou D, Zhang Y. Sintilimab and chidamide for refractory transformed diffuse large b cell lymphoma: a case report and a literature review. Front Oncol. 2021;11:757403. doi:10.3389/fonc.2021.757403
   PubMed Web of Science ®Google Scholar
• Tu K, Yu Y, Wang Y, et al. Combination of chidamide-mediated epigenetic modulation with immunotherapy: boosting tumor immunogenicity and response TO PD-1/PD-L1 Blockade. ACS Appl Mater Interfaces. 2021;13(33):39003–39017. doi:10.1021/acsami.1c08290
   PubMed Web of Science ®Google Scholar
• Que Y, Zhang XL, Liu ZX, et al. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. J Immunother Cancer. 2021;9(2):e001696. doi:10.1136/jitc-2020-001696
   PubMed Web of Science ®Google Scholar
• Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(6):806–815. doi:10.1016/S1470-2045(19)30164-0
   PubMed Web of Science ®Google Scholar
• De Martino M, Daviaud C, Vanpouille-Box C. Radiotherapy: an immune response modifier for immuno-oncology. Semin Immunol. 2021;52:101474. doi:10.1016/j.smim.2021.101474
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu ZG, Yuan H, et al. The reciprocity between radiotherapy and cancer immunotherapy. Clin Cancer Res. 2019;25(6):1709–1717. doi:10.1158/1078-0432.CCR-18-2581
   PubMed Web of Science ®Google Scholar
• Zeng H, Zhang W, Gong Y, Xie C. Radiotherapy activates autophagy to increase CD8(+) T cell infiltration by modulating major histocompatibility complex class-I expression in non-small cell lung cancer. J Int Med Res. 2019;47(8):3818–3830. doi:10.1177/0300060519855595
   PubMed Web of Science ®Google Scholar
• Du SS, Chen GW, Yang P, et al. Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys. 2022;112(5):1243–1255. doi:10.1016/j.ijrobp.2021.12.162
   PubMed Web of Science ®Google Scholar
• Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611–1618. doi:10.1200/JCO.2017.76.2229
   PubMed Web of Science ®Google Scholar
• Zhai D, An D, Wan C, Yang K. Radiotherapy: brightness and darkness in the era of immunotherapy. Transl Oncol. 2022;19:101366. doi:10.1016/j.tranon.2022.101366
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–379. doi:10.1038/nrclinonc.2016.211
   PubMed Web of Science ®Google Scholar
• Brandmaier A, Formenti SC. The impact of radiation therapy on innate and adaptive tumor immunity. Semin Radiat Oncol. 2020;30(2):139–144. doi:10.1016/j.semradonc.2019.12.005
   PubMed Web of Science ®Google Scholar
• Herrera FG, Ronet C, Ochoa de Olza M, et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12(1):108–133. doi:10.1158/2159-8290.CD-21-0003
   PubMed Web of Science ®Google Scholar
• Turchan WT, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy combinations in the treatment of patients with metastatic disease: current status and future focus. Clin Cancer Res. 2021;27(19):5188–5194. doi:10.1158/1078-0432.CCR-21-0145
   PubMed Web of Science ®Google Scholar
• Blattmann C, Oertel S, Thiemann M, et al. Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiat Oncol. 2015;10(1):146. doi:10.1186/s13014-015-0455-z
   PubMedGoogle Scholar
• Wang Y, Jin T, Dai X, Yan D, Peng Z. Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells. Mol Med Rep. 2016;14(4):3509–3516. doi:10.3892/mmr.2016.5711
   PubMed Web of Science ®Google Scholar
• Baschnagel A, Russo A, Burgan WE, et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther. 2009;8(6):1589–1595. doi:10.1158/1535-7163.MCT-09-0038
   PubMed Web of Science ®Google Scholar
• Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi:10.1136/bmj.e7586
   PubMed Web of Science ®Google Scholar